The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Inhibition of tumor angiogenesis by cannabinoids
Abstract
Cannabinoids, the active components of marijuana and their derivatives, induce tumor regression in rodents (8). However, the mechanism of cannabinoid antitumoral action in vivo is as yet unknown. Here we show that local administration of a nonpsychoactive cannabinoid to mice inhibits angiogenesis of malignant gliomas as determined by immunohistochemical analyses and vascular permeability assays. In vitro and in vivo experiments show that at least two mechanisms may be involved in this cannabinoid action: the direct inhibition of vascular endothelial cell migration and survival as well as the decrease of the expression of proangiogenic factors (vascular endothelial growth factor and angiopoietin‐2) and matrix metalloproteinase‐2 in the tumors. Inhibition of tumor angiogenesis may allow new strategies for the design of cannabinoid‐based antitumoral therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070 · cited 4×
“Cannabinoid administration was associated with a notable decrease in the expression of the major proangiogenic factors VEGF and Ang2, which are essential for the vascularization of gliomas and many other types of tumors such as those from mammary gland, lung, and skin (13, 22, 26, 27).”
BackgroundInfluentialIsolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 1×
“Two different cannabinoid receptors have been characterized and cloned from mammalian tissues: the central CB1 receptor, which is responsible for cannabinoid psychoactivity (24), and the peripheral CB2 receptor, which is unrelated to cannabinoid psychoactivity (25).”
BackgroundStructure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
Mechanisms of angiogenesis and arteriogenesis
Carmeliet, P. (2000) · Nature Medicine · doi:10.1038/74651 · Cited by 4,162
Vascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · cited 2×
“In line with the idea that antiangiogenic treatments constitute one of the most promising antitumoral approaches currently available (13, 14), the present findings provide a novel pharmacological target for cannabinoid-based therapies.”
BackgroundMechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
Formation and inactivation of endogenous cannabinoid anandamide in central neurons
Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.-C., & Piomelli, D. (1994) · Nature · doi:10.1038/372686a0 · Cited by 1,587
Matrix Metalloproteinases: Biologic Activity and Clinical Implications
Nelson, A. R., Fingleton, B., Rothenberg, M. L., & Matrisian, L. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.5.1135 · Cited by 1,554
Histological Typing of Tumours of the Central Nervous System
Kleihues, P., Burger, P. C., & Scheithauer, B. W. (1993) · Springer eBooks · doi:10.1007/978-3-642-84988-6 · Cited by 1,532
Cited by
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Cannabinoids and the expanded endocannabinoid system in neurological disorders
Cristino, L., Bisogno, T., & Di Marzo, V. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0284-z · Cited by 970
Cannabinoids: potential anticancer agents
Guzmán, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1188 · Cited by 703
Self-citationCannabidiol: State of the art and new challenges for therapeutic applications
Pisanti, S., Malfitano, A. M., Ciaglia, E., Lamberti, A., Ranieri, R., Cuomo, G., Abate, M., Faggiana, G., Proto, M. C., Fiore, D., et al. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.041 · Cited by 614
The cannabinoid system and immune modulation
Klein, T. W., Newton, C., Larsen, K., Lu, L., Perkins, I., Nong, L., & Friedman, H. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0303101 · Cited by 524
Ligresti, A., De Petrocellis, L., & Di Marzo, V. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 469
Towards the use of cannabinoids as antitumour agents
Velasco, G., Sánchez, C., & Guzmán, M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3247 · Cited by 372
Self-citationA pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme
Guzmán, M., Duarte, M. J., Blázquez, C., Ravina, J., Rosa, M. C., Galve-Roperh, I., Sánchez, C., Velasco, G., & González-Feria, L. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603236 · Cited by 365
Self-citationCannabinoid CB2 receptor: a new target for controlling neural cell survival?
Fernández-Ruiz, J., Romero, J., Velasco, G., Tolón, R. M., Ramos, J. A., & Guzmán, M. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.11.001 · Cited by 362
Self-citationCarracedo, A., Gironella, M., Lorente, M., Garcia, S., Guzmán, M., Velasco, G., & Iovanna, J. L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0169 · Cited by 354
The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells
Carracedo, A., Lorente, M., Egia, A., Blázquez, C., García, S., Giroux, V., Malicet, C., Villuendas, R., Gironella, M., González-Feria, L., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.005 · Cited by 352
Self-citationThe Endocannabinoid System: Drug Targets, Lead Compounds, and Potential Therapeutic Applications
Lambert, D. M., & Fowler, C. J. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058183t · Cited by 350
Programming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies
Maccarrone, M., Guzmán, M., Mackie, K., Doherty, P., & Harkany, T. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3846 · Cited by 298
Self-citationStänder, S., Schmelz, M., Metze, D., Luger, T., & Rukwied, R. (2005) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2005.01.007 · Cited by 298
Cannabinoid receptors as novel targets for the treatment of melanoma
Blázquez, C., Carracedo, A., Barrado, L., José Real, P., Luis Fernández‐Luna, J., Velasco, G., Malumbres, M., Guzmán, M., Blázquez, C., Carracedo, A., et al. (2006) · The FASEB Journal · doi:10.1096/fj.06-6638fje · Cited by 292
Self-citationNeuroprotective and Blood-Retinal Barrier-Preserving Effects of Cannabidiol in Experimental Diabetes
El-Remessy, A. B., Al-Shabrawey, M., Khalifa, Y., Tsai, N.-T., Caldwell, R. B., & Liou, G. I. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.050500 · Cited by 274
Anticancer Mechanisms of Cannabinoids
Velasco, G., Sánchez, C., & Guzmán, M. (2016) · Current Oncology · doi:10.3747/co.23.3080 · Cited by 265
Self-citationRajesh, M., Mukhopadhyay, P., Bátkai, S., Haskó, G., Liaudet, L., Huffman, J. W., Csiszar, A., Ungvari, Z., Mackie, K., Chatterjee, S., et al. (2007) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00688.2007 · Cited by 260
Self-citationAlkylamides from Echinacea Are a New Class of Cannabinomimetics
Raduner, S., Majewska, A., Chen, J.-Z., Xie, X.-Q., Hamon, J., Faller, B., Altmann, K.-H., & Gertsch, J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601074200 · Cited by 258
Cannabinoids Inhibit the Vascular Endothelial Growth Factor Pathway in Gliomas
Blázquez, C., González-Feria, L., Álvarez, L., Haro, A., Casanova, M. L., & Guzmán, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3927 · Cited by 255
Self-citationEndocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.
Pacher, P., & Haskó, G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707582 · Cited by 217
Antitumorigenic effects of cannabinoids beyond apoptosis.
Freimuth, N., Ramer, R., & Hinz, B. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.157735 · Cited by 71
Cannabinoid receptor systems: therapeutic targets for tumour intervention.
Jones, S., & Howl, J. (2003) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.7.6.749 · Cited by 13
Metadata
- Authors
- Blázquez, C., Casanova, M. L., Planas, A., Gómez del Pulgar, T., Villanueva, C., Fernández‐Aceñero, M. J., Aragonés, J., Huffman, J. W., Jorcano, J. L., & Guzmán, M.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2003-01-02
- Volume
- 17
- Issue
- 3
- Pages
- 1-16
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2144403540
- Cited by
- 292
- References
- 44
- FWCI
- 10.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.